IVIG Shows No Impact on VTE Risk in Dermatomyositis Patients

The rate of venous thromboembolism did not increase in dermatomyositis patients treated with intravenous immunoglobulin, compared with those not treated with IVIG.
MDedge News

source https://www.medscape.com/viewarticle/991881?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?